Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform ...
Bright Minds Biosciences is rated Hold due to heavy dilution, overvaluation, and reliance on a single late-stage asset, BMB-101. BMB-101 targets drug-resistant epilepsies with strong Phase 2 results ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results